TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03331536

Intervention type: PROCEDURE
Intervention: Roux en Y Gastric Bypass Pre-menopausal
Description: The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.

Intervention type: PROCEDURE
Intervention: Roux en Y Gastric Bypass Post-menopausal
Description: The investigator aims to determine changes in skeletal health after Roux en Y Gastric Bypass in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.

Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy Pre-menopausal
Description: The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in pre-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.

Intervention type: PROCEDURE
Intervention: Sleeve Gastrectomy Post-menopausal
Description: The investigator aims to determine changes in skeletal health after Sleeve Gastrectomy in post-menopausal women. Dual-energy x-ray absorptiometry (DXA) will be used to assess bone mineral density (BMD), including assessment for fracture risk (FRAX). Trabecular Bone Score (TBS) software will be used to adjust FRAX scores for bone microstructure and an enhanced fracture risk probability. Biochemical markers of bone metabolism and calcium homeostasis including serum bone alkaline phosphatase (BALP), osteocalcin, type 1 procollagen (P1NP), c-terminal telopeptide (CTX), calcium, albumin, parathyroid hormone (PTH), and 25-OH vitamin D will be assayed.
Study: NCT03954860

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drainage Tube
Description: The drainage tube drainage to guide the pus, blood and liquid accumulated between human tissues or in body cavity outside the body of High tibial osteotomy'patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid (TXA) is an anti-fibrinolytic drugcan，which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride 0.9%
Description: Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
Study: NCT02163148

Intervention type: BEHAVIORAL
Intervention: Massed speech exposure session
Description: One session consisting of 4 speech exposures, each 5 minutes long.
Study: NCT00831948

Intervention type: GENETIC
Intervention: mitochondrial DNA mutations diagnosis
Description: Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
Study: NCT03760653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise and probiotic group
Description: The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of \~ 60 min duration (aerobic and strength combined training). The exercise sessions will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a authorized fitness center and it will be supervised and individualized for each subject by expert professionals.The probiotic will be taken (3 capsules/day) for 12 weeks. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic group
Description: Probiotic supplementation (3 capsules/day) will be taken before bedtime for 12 weeks.Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Subjects will take 3 capsules/day of placebo capsules (maltodextrin) for 12 weeks
Study: NCT03177226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional TENS stimulation
Description: A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
Study: NCT04361604

Intervention type: OTHER
Intervention: Auto-questionnaires (patients co infected HIV Sras-CoV-2)
Description: 4 autoquestionnaires will be collected : HADS Hospital anxiety and depression scale, PCL-5 (post-traumatic stress disorder checklist version DSM-5), symptoms with the modified Justice Symptom Index PROQOL-HIV

Intervention type: OTHER
Intervention: Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)
Description: Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
Study: NCT03177226

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-Functional TENS stimulation
Description: A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
Study: NCT03192709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil vaginal suppositories
Description: Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vaginal placebo
Description: Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vaginal placebo
Description: Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
Study: NCT04361604

Intervention type: OTHER
Intervention: Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)
Description: Qualitative interviews will be realized in 40 patients (20 with COVID-19 and 20 without COVID-19)
Study: NCT03999138

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI studies (non-contrast) will consist of a free-breathing localizer (\~10 seconds) followed by a free-breathing yarnball water density scan, for a total MRI time of \< 3 minutes.
Study: NCT02145104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg
Study: NCT01536418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786A
Description: 500 milligrams once daily, orally administered for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786A
Description: 500 milligrams twice daily, orally adminstered for 12 weeks
Study: NCT02145104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg
Study: NCT00197145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW873140
Description: 400 mg twice daily
Study: NCT02147223

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavanol rich intervention
Description: Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol rich intervention
Description: Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol rich intervention
Description: Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol rich intervention
Description: Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol free intervention
Description: Calorically, micro- and macronutrient matched control product free of flavanols

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol free intervention
Description: Calorically, micro- and macronutrient matched control product free of flavanols

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavanol free intervention
Description: Calorically, micro- and macronutrient matched control product free of flavanols
Study: NCT03698045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-143 Ophthalmic Solution
Description: PRO-143 Ophthalmic Solution applied four times per day (C/6 hours) during 10 days.
Study: NCT01579825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buffer
Description: 5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
Study: NCT04911244

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchoalveolar lavage
Description: endobronchial sampling through bronchoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: bronchoalveolar lavage
Description: endobronchial sampling through bronchoscopy
Study: NCT01258153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant oral solution
Description: Oral administration once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepadutant oral solution
Description: Oral administration once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Nepadutant oral solution
Description: Oral administration once daily for 7 days
Study: NCT02161458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20mg for 2 weeks
Description: 30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20mg for 8 weeks
Description: 30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 30mg for 8 weeks
Description: 30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
Study: NCT03056378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Standard RBCs
Description: Transfusion of standard pRBCs that are matched for C, E and K

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard RBCs
Description: Transfusion of standard pRBCs that are matched for C, E and K
Study: NCT00774878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: AVE1642 is administered intravenously at the dose of 8 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
Study: NCT04534738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: The Mediterranean Diet is high in fruit, vegetables, legumes, nuts and seeds, whole grains, and olive oil; moderate in seafood, dairy products (e.g., cheese and yogurt but not whole milk or butter), eggs, poultry, and red wine with meals; and low consumption of sweet desserts, red meat, and highly processed foods.
Study: NCT02384382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study: NCT02604693

Intervention type: OTHER
Intervention: Nothing
Description: No interventions will be administered.
Study: NCT04805203

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample analyses
Description: maximum 4 blood samples analyses per patient. At diagnosis of covid 19, in intensif care (if applicable), at covid19 recovery and 6 months after recovery
Study: NCT02737553

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enclosed morcellation
Description: After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal morcellation
Description: After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
Study: NCT01082510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacille Calmette-Guerin
Description: The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uracil-tegafur
Description: The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
Study: NCT02604693

Intervention type: OTHER
Intervention: Nothing
Description: No interventions will be administered.

Intervention type: OTHER
Intervention: Nothing
Description: No interventions will be administered.
Study: NCT02410278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: As described in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched placebo
Study: NCT03076853

Intervention type: OTHER
Intervention: Opening of the Pharmaceutical Record
Description: After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
Study: NCT00148122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
Study: NCT00293709

Intervention type: DRUG
Intervention: etanercept
Description: The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study: NCT00571636

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.~Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is \> 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% glucose solution
Description: ev continuous infusion
Study: NCT04589351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10mg
Description: Ezetimibe is a cholesterol absorption inhibitor with marketing approval. The recommended dose as per label is 10mg once a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03795207

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT + Durvalumab
Description: Durvalumab, MEDI4736, is a immunotherapy,~SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT
Description: SBRT (stereotactic body radiotherapy) is a procedure that uses high doses of radiation delivered to a precise target. By using special positioning and implanted markers in the body, radiologists are able to deliver a much higher dose of radiation to a cancer than traditional radiation therapy
Study: NCT05366491

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Il-38 serum level
Description: measurement of serum levels of IL-38

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Il-38 serum level
Description: measurement of serum levels of IL-38
Study: NCT03310008

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 cells
Description: The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
Study: NCT04179565

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Children Healthy Families
Description: The Healthy Children, Healthy Families: Parents Making a Difference! intervention was developed by the investigators for low-income parents and caregivers focusing on the behaviors most likely to help children avoid unhealthy weight gain.
Study: NCT03493009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Description: The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pure-Vu System
Description: The Pure-Vu System is Food and Drug Administration (FDA) approved device since September 22, 2016, intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating or cleaning the colon and evacuating the irrigation fluid (water), feces and other bodily fluids and matter, e.g. blood.